Andreef et al 2009 evaluated 119 adult AML cases and that found 20% and 10% long-term survival amongst patients with intermediate or high levels of HOXA9, respectively, compared with 40% survival amongst patients with low-level HOXA9; in addition, they noted that patients with low-level HOXA9 mainly had favorable cytogenetics, i.e. t(15;17), t(8;21), or inv(16). The gene discussed is HOXA9; the disease is acute myeloid leukemia.